Deep dive: Bioprocess scale-up & biomanufacturing economics — what's working, what's not, and what's next

The biomanufacturing sector is confronting a defining challenge: the gap between laboratory success and commercial-scale production economics. Companies that demonstrated promising fermentation, enzymatic, and cell-culture processes at bench scale are now discovering that scaling to 10,000-liter and 100,000-liter bioreactors introduces cost structures, yield losses, and operational complexities that laboratory results never predicted. Understanding where scale-up economics actually work, where they consistently fail, and what emerging approaches might close the gap is critical for sustainability leaders evaluating bio-based alternatives to petrochemical and conventional manufacturing processes.

Why It Matters

Biomanufacturing represents one of the most significant potential levers for industrial decarbonization. The US Department of Energy estimates that bio-based production could eventually displace up to 30% of petroleum-derived chemicals and materials, reducing industrial greenhouse gas emissions by 1.2 to 2.4 gigatonnes of CO2 equivalent annually. The Biden administration's 2022 Executive Order on Advancing Biotechnology and Biomanufacturing Innovation set a national goal to expand US biomanufacturing capacity, backed by over $2 billion in federal investment through the Biotechnology and Biomanufacturing Initiative.

The economic stakes are substantial. McKinsey estimated the total addressable market for bio-based chemicals, materials, and fuels at $200 to $300 billion by 2030, with the potential to reach $500 billion by 2040. However, capturing this market requires solving the scale-up cost problem. As of 2025, fewer than 20% of biomanufacturing startups that raised Series A or later funding have successfully achieved production costs competitive with incumbent petrochemical processes at commercial volumes, according to analysis by Synonym, a biomanufacturing infrastructure company.

The investment landscape reflects both opportunity and caution. Venture capital deployed into industrial biotechnology totaled approximately $4.8 billion in 2024, down from a peak of $7.2 billion in 2021, according to PitchBook data. This correction reflects investor recognition that promising laboratory economics do not automatically translate to commercial viability. The survivors of this market correction will be companies that solve specific, quantifiable scale-up challenges rather than those relying on optimistic extrapolation from small-scale results.

For sustainability leaders, the practical question is not whether biomanufacturing will eventually succeed but which applications are economically viable today, which are likely to become viable within 3 to 5 years, and which remain fundamentally constrained by physics and economics that no amount of engineering optimization can overcome.

Key Concepts

Fermentation Scale-Up involves transitioning microbial production from laboratory flasks (typically 1 to 10 liters) through pilot-scale bioreactors (100 to 1,000 liters) to commercial-scale vessels (10,000 to 200,000 liters). Each scale transition introduces new challenges: oxygen transfer rates change non-linearly with vessel size, mixing becomes heterogeneous in large tanks, and thermal management requires increasingly sophisticated control systems. The general rule of thumb is that each 10x scale increase requires 18 to 24 months of process development and $5 to $15 million in capital expenditure.

Techno-Economic Analysis (TEA) is the systematic evaluation of production costs, capital requirements, and revenue potential for a bioprocess at various scales. Rigorous TEA incorporates feedstock costs, utility consumption, labor requirements, equipment depreciation, downstream processing costs, and yield assumptions validated at the target scale. The most common failure mode in biomanufacturing business plans is TEA based on laboratory yields and bench-scale process parameters, which systematically underestimate production costs at commercial scale by 40 to 200%.

Downstream Processing (DSP) encompasses all steps required to purify a target molecule from the fermentation broth, including cell separation, extraction, chromatography, crystallization, and formulation. DSP frequently accounts for 50 to 80% of total production costs for high-purity products, and its economics often determine overall process viability. Many biomanufacturing companies that achieve excellent fermentation titers discover that their DSP costs make the overall process uneconomic.

Continuous Bioprocessing replaces traditional batch fermentation (where a bioreactor is filled, run to completion, and emptied) with systems that continuously feed nutrients and harvest product. Continuous processes can achieve 3 to 5x higher volumetric productivity than batch systems, reduce downtime, and improve product consistency. However, they require more sophisticated process control, face contamination management challenges, and demand higher initial capital investment.

Contract Development and Manufacturing Organizations (CDMOs) provide biomanufacturing capacity and expertise to companies that lack their own production facilities. The CDMO model allows startups to access commercial-scale production without the $50 to $200 million capital expenditure required to build a dedicated facility, but it introduces dependency on external capacity, potential intellectual property risks, and limited ability to optimize processes for specific products.

What's Working

Precision Fermentation for High-Value Ingredients

Precision fermentation, which uses engineered microorganisms to produce specific proteins, enzymes, or other molecules, has achieved commercial-scale economics for products commanding premium prices. Perfect Day (now The Urgent Company) produces animal-free whey proteins using engineered Trichoderma fungi at production costs that achieve margin-positive operations when selling to premium food and beverage brands. Their facility in Marysville, Michigan, operates 50,000-liter bioreactors with yields exceeding 30 grams per liter, a threshold that the company identified as the breakeven point for its specific product and market positioning.

Similarly, Impossible Foods' production of soy leghemoglobin (the key ingredient in its plant-based meat products) via engineered Pichia pastoris yeast has scaled successfully to commercial volumes. The company's Oakland, California, facility and contract manufacturing partnerships produce sufficient heme protein for over 100 million pounds of product annually. Production costs for the heme ingredient declined approximately 90% between 2017 and 2024 through a combination of strain engineering (improving titers from 3 to over 25 grams per liter), process optimization, and manufacturing scale.

The common denominator in successful precision fermentation scale-ups is product value. Processes that produce molecules selling for $5 to $50 per kilogram at commodity scale have struggled to achieve cost competitiveness. Those producing ingredients that sell for $50 to $500 per kilogram or higher have consistently better economics because the revenue per fermentation run can absorb the fixed costs of commercial-scale operations.

Industrial Enzyme Production

The industrial enzyme sector, led by Novozymes (now Novonesis following its 2024 merger with Chr. Hansen) and DSM-Firmenich, represents the most mature segment of biomanufacturing. These companies operate fermentation facilities at scales exceeding 200,000 liters with decades of accumulated process knowledge. Production costs for bulk industrial enzymes (used in laundry detergent, food processing, and textile manufacturing) have declined to $5 to $15 per kilogram, making them fully cost-competitive with chemical alternatives for many applications.

The enzyme industry's success offers transferable lessons. Novonesis achieves manufacturing efficiencies through: standardized fermentation platforms that accommodate multiple products with minimal changeover costs; integrated DSP processes optimized over decades of continuous improvement; and co-location strategies that share utility infrastructure across multiple production lines. Their Kalundborg, Denmark, facility exemplifies industrial symbiosis, exchanging steam, water, and biomass with neighboring industrial operations to reduce per-unit utility costs by approximately 30%.

Biopolymer Production at Mid-Scale

Several biopolymer companies have achieved commercially viable production at intermediate scale. Danimer Scientific produces polyhydroxyalkanoate (PHA) bioplastics at its Winchester, Kentucky, facility using canola oil as a feedstock. While not yet cost-competitive with commodity polyethylene at bulk volumes, PHA commands a 2 to 3x price premium in applications where compostability and marine biodegradability provide regulatory or consumer value. The company's production costs declined approximately 35% between 2022 and 2025 through process optimization, reaching approximately $2.50 to $3.00 per kilogram at current scale.

What's Not Working

Commodity Chemical Production via Fermentation

Attempts to produce bulk commodity chemicals (such as succinic acid, 1,4-butanediol, and adipic acid) through fermentation have largely failed to achieve cost parity with petrochemical production at current oil prices. BioAmber, which raised over $200 million to produce bio-based succinic acid, filed for bankruptcy in 2018 after its Sarnia, Ontario, facility could not achieve production costs below $1.80 per kilogram against a petrochemical price of $1.00 to $1.20 per kilogram. LanzaTech's gas fermentation technology, which converts industrial waste gases to ethanol and other chemicals, has demonstrated technical viability but continues to require capital subsidies and favorable feedstock pricing to achieve positive unit economics.

The fundamental challenge is that petrochemical processes benefit from 80+ years of continuous optimization, massive infrastructure investment, and feedstock costs linked to relatively cheap natural gas and petroleum. Bio-based alternatives face not only higher production costs but also the capital expenditure required to build greenfield manufacturing capacity competing against fully depreciated petrochemical assets.

Cell-Cultured Meat at Consumer Price Points

Cultivated meat companies have struggled to close the gap between production costs and consumer price expectations. Upside Foods and GOOD Meat (Eat Just) received FDA and USDA approvals for cultivated chicken in June 2023, but production costs remain in the range of $20 to $50 per kilogram according to industry estimates, compared to conventional chicken prices of $3 to $6 per kilogram at wholesale. The primary cost drivers are cell culture media (which accounts for 50 to 80% of production costs despite significant optimization efforts), bioreactor capital costs, and the energy required to maintain sterile, temperature-controlled environments at scale.

The Open Philanthropy-funded TEA published by CE Delft in 2023 projected that cultivated meat could reach $5 to $10 per kilogram by 2030 under optimistic assumptions about media cost reduction, cell density improvements, and manufacturing scale. However, these projections require simultaneous breakthroughs across multiple technical dimensions, and no single company has demonstrated all required improvements at pilot scale, let alone commercial production.

Algae-Based Fuels and Bulk Materials

Despite receiving over $2 billion in combined government and private investment over the past 15 years, algae-based biofuels have not achieved cost-competitive production. The fundamental constraint is biological: algae photosynthesize with approximately 3 to 6% solar energy conversion efficiency, and achieving the cell densities required for economic harvesting and extraction creates self-shading that limits productivity. Companies including Sapphire Energy, Solazyme (now TerVia), and Algenol pivoted away from fuel production toward higher-value products (cosmetics, nutrition, specialty chemicals) after concluding that algae-to-fuel economics were unviable at any foreseeable scale.

What's Next

AI-Driven Bioprocess Optimization

Machine learning is beginning to accelerate bioprocess development and reduce the time and cost of scale-up. Zymergen (acquired by Ginkgo Bioworks in 2022) pioneered the application of robotic automation and machine learning to strain engineering, though it ultimately struggled with commercial execution. Ginkgo Bioworks now operates the largest biological foundry in the world, processing over 100,000 engineered organisms per month and using AI models to predict fermentation behavior at scale from small-scale experimental data. Their platform has reduced the time from strain identification to pilot-scale validation from 18 to 24 months to 6 to 9 months for certain product categories.

Culture Biosciences (acquired by National Resilience in 2024) developed cloud-connected miniature bioreactors that generate scale-down data predictive of commercial-scale performance. By running hundreds of parallel experiments with automated data collection, their platform reduces the number of expensive pilot-scale runs required to optimize a process. Early results suggest a 40 to 60% reduction in total scale-up development costs for clients using the platform.

Modular and Distributed Manufacturing

Rather than building massive centralized facilities, several companies are pursuing modular biomanufacturing approaches. Synonym (formerly known as Synonym Biotechnologies) is developing standardized, pre-engineered biomanufacturing facilities that can be deployed in 12 to 18 months compared to 3 to 5 years for conventional greenfield construction. Their modular design targets 50,000 to 100,000 liter total fermentation capacity per module, with standardized DSP trains that can be configured for multiple product types.

The modular approach addresses several pain points: it reduces upfront capital requirements from $100 to $200 million to $30 to $60 million per module; it enables phased capacity expansion aligned with market demand; and it allows co-location with feedstock sources (agricultural regions) or customers (chemical manufacturing hubs) to reduce logistics costs.

Consolidated Bioprocessing and Cell-Free Systems

Cell-free biomanufacturing, which uses purified enzymes rather than living cells to catalyze chemical transformations, eliminates many of the challenges associated with maintaining viable cell cultures at scale. Solugen operates a cell-free enzymatic process to produce hydrogen peroxide and glucaric acid at its Houston, Texas, facility, achieving production costs competitive with petrochemical alternatives. The process runs at ambient temperature and pressure, dramatically reducing energy costs compared to conventional fermentation.

Consolidated bioprocessing (CBP), which combines enzyme production, substrate hydrolysis, and product fermentation in a single step, is showing promise for lignocellulosic biorefining. LanzaTech's gas fermentation and POET-DSM's Project Liberty cellulosic ethanol facility in Emmetsburg, Iowa, represent different approaches to consolidating multiple processing steps into more efficient, lower-cost configurations.

Key Players

Ginkgo Bioworks operates the world's largest biological foundry and is positioning itself as a platform provider for biomanufacturing process development.

Novonesis (formerly Novozymes + Chr. Hansen) is the global leader in industrial enzyme production with the most mature large-scale fermentation operations.

National Resilience is building a network of biomanufacturing facilities focused on reducing the time and cost of scale-up for pharmaceutical and industrial biotech clients.

Solugen has demonstrated cell-free enzymatic manufacturing at commercial scale for commodity chemicals.

Synonym is developing standardized modular biomanufacturing infrastructure to reduce capital costs and construction timelines.

DSM-Firmenich combines deep fermentation expertise with a global manufacturing footprint spanning food ingredients, nutrition, and materials.

Action Checklist

• Require rigorous TEA validated at pilot scale (minimum 1,000 liters) before committing capital to commercial-scale biomanufacturing
• Evaluate DSP costs independently from fermentation economics, as purification frequently dominates total production cost
• Assess feedstock cost sensitivity: model production economics at 50%, 100%, and 150% of current feedstock prices
• Consider CDMO partnerships for initial commercial volumes to de-risk capital expenditure before building dedicated facilities
• Benchmark target production costs against petrochemical incumbents at current and projected oil/gas prices
• Evaluate modular manufacturing approaches for products with uncertain demand trajectories
• Prioritize products with $50+ per kilogram selling prices for near-term biomanufacturing investments
• Build 18 to 24 month contingency into scale-up timelines to account for the iterative optimization typically required at each scale transition

FAQ

Q: What is a realistic timeline for scaling a bioprocess from lab to commercial production? A: Plan for 4 to 7 years from validated laboratory strain to steady-state commercial production. This includes 12 to 18 months for strain optimization, 18 to 24 months for pilot-scale development and TEA validation, 12 to 18 months for facility construction or CDMO contract negotiation, and 6 to 12 months for commissioning and production ramp-up. Companies that claim faster timelines typically underestimate the iterative optimization required at each scale transition.

Q: What production cost reduction is typical when moving from pilot to commercial scale? A: Cost reductions of 30 to 60% between pilot and commercial scale are typical for well-optimized processes. The reduction comes from: economies of scale in feedstock procurement (10 to 20% savings), improved labor productivity (larger batches with similar staffing), utility cost amortization over larger volumes, and yield improvements from process optimization at scale. However, some costs increase at scale, particularly quality control, regulatory compliance, and waste treatment, which partially offset volumetric savings.

Q: How should investors evaluate biomanufacturing companies' cost projections? A: Focus on three indicators. First, verify that claimed production costs are validated at a minimum of 1,000-liter scale, not extrapolated from bench experiments. Second, examine the ratio of DSP costs to total costs; if DSP exceeds 60% of total production cost, the process likely requires fundamental redesign rather than incremental optimization. Third, compare the projected production cost to the selling price of the incumbent (petrochemical) product; a bio-based product needs to be within 20 to 30% of incumbent pricing to succeed without regulatory mandates, or the company needs a credible path to a price premium market.

Q: What role does feedstock cost play in biomanufacturing economics? A: Feedstock typically represents 25 to 45% of total production cost for sugar-based fermentation and 15 to 30% for gas fermentation. Sugar prices (corn-derived glucose in North America, sugarcane-derived sucrose in Brazil) have ranged from $200 to $400 per tonne over the past five years, introducing significant volatility into production economics. Companies with processes that can use lower-cost, second-generation feedstocks (agricultural residues, food waste, industrial off-gases) have a structural cost advantage, but the additional pretreatment steps required for these feedstocks add complexity and capital cost.

Q: Are government incentives changing biomanufacturing economics? A: Significantly. The US Inflation Reduction Act provides production tax credits for sustainable aviation fuel produced via bio-based pathways, valued at $1.25 to $1.75 per gallon depending on lifecycle emissions reduction. The USDA BioPreferred program mandates federal procurement preferences for bio-based products. The EU's proposed Net Zero Industry Act includes biomanufacturing among strategic technologies eligible for accelerated permitting and financial support. These incentives do not eliminate the need for competitive production costs but can bridge the gap for processes that are within 20 to 40% of petrochemical cost parity.

Sources

• US Department of Energy. (2025). Biomanufacturing for a Sustainable Industrial Future: National Strategy Update. Washington, DC.
• McKinsey & Company. (2024). The Bio Revolution: Innovations Transforming Economies, Societies, and Our Lives (2024 Update). New York.
• PitchBook Data. (2025). Industrial Biotechnology Venture Capital Annual Report 2024. Seattle, WA.
• Synonym. (2025). State of Biomanufacturing Infrastructure: Capacity, Costs, and Gaps. New York.
• CE Delft. (2023). Techno-Economic Assessment of Cultivated Meat: Costs, Scale-Up, and Market Viability. Delft, Netherlands.
• National Academies of Sciences, Engineering, and Medicine. (2024). Safeguarding the Bioeconomy: Scaling Biomanufacturing in the United States. Washington, DC: The National Academies Press.
• International Energy Agency. (2024). The Role of Bioenergy and Biomanufacturing in Net Zero Transitions. Paris: IEA Publications.